中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
12期
30-31
,共2页
雷景芬%冯彩虹%李云峰%孙瑜
雷景芬%馮綵虹%李雲峰%孫瑜
뢰경분%풍채홍%리운봉%손유
非瓣膜性房颤%华法令%阿司匹林%通心络胶囊%脑栓塞
非瓣膜性房顫%華法令%阿司匹林%通心絡膠囊%腦栓塞
비판막성방전%화법령%아사필림%통심락효낭%뇌전새
Nonvalvular atrial fibrillation%Warfarin%Aspirin%Tongxinluo capsule%Cerebral thromboembolism
目的:探讨抗凝治疗非瓣膜性房颤(NVAF)的临床效果及药物选择。方法回顾性分析本院近5年内科住院治疗的NVAF患者96例,随机分为华法令组32例,予华法令1.25~5 mg/d,维持国际标准化比值(INR)2.0~3.0;通心络胶囊联合阿司匹林组32例,予通心络胶囊0.78 g,3次/d,阿司匹林片100 mg/d;阿司匹林组32例,予阿司匹林片100 mg/d。观察和比较三组患者脑栓塞及出血等并发症发生率,随访2年。结果脑栓塞年发病率华法令组(3.33%)与通心络胶囊联合阿司匹林组(5.0%)比较差异无统计学意义(P>0.05);阿司匹林组(17.2%)与通心络胶囊联合阿司匹林组比较差异有统计学意义(P<0.05);华法令组与阿司匹林组比较差异有统计学意义(P<0.01)。华法令组有1例脑出血;通心络胶囊联合阿司匹林组有4例出现上腹痛、恶心,1例出现牙龈肿痛;阿司匹林组有3例出现上腹痛、恶心。结论通心络胶囊联合阿司匹林预防NVAF患者脑栓塞的效果和华法令比较差异无统计学意义,优于单用阿司匹林,无严重不良反应发生,且不需要监测凝血酶原时间(PT)和INR。不愿意接受华法令治疗的NVAF患者,给予通心络胶囊联合阿司匹林预防脑栓塞并发症是安全有效的。
目的:探討抗凝治療非瓣膜性房顫(NVAF)的臨床效果及藥物選擇。方法迴顧性分析本院近5年內科住院治療的NVAF患者96例,隨機分為華法令組32例,予華法令1.25~5 mg/d,維持國際標準化比值(INR)2.0~3.0;通心絡膠囊聯閤阿司匹林組32例,予通心絡膠囊0.78 g,3次/d,阿司匹林片100 mg/d;阿司匹林組32例,予阿司匹林片100 mg/d。觀察和比較三組患者腦栓塞及齣血等併髮癥髮生率,隨訪2年。結果腦栓塞年髮病率華法令組(3.33%)與通心絡膠囊聯閤阿司匹林組(5.0%)比較差異無統計學意義(P>0.05);阿司匹林組(17.2%)與通心絡膠囊聯閤阿司匹林組比較差異有統計學意義(P<0.05);華法令組與阿司匹林組比較差異有統計學意義(P<0.01)。華法令組有1例腦齣血;通心絡膠囊聯閤阿司匹林組有4例齣現上腹痛、噁心,1例齣現牙齦腫痛;阿司匹林組有3例齣現上腹痛、噁心。結論通心絡膠囊聯閤阿司匹林預防NVAF患者腦栓塞的效果和華法令比較差異無統計學意義,優于單用阿司匹林,無嚴重不良反應髮生,且不需要鑑測凝血酶原時間(PT)和INR。不願意接受華法令治療的NVAF患者,給予通心絡膠囊聯閤阿司匹林預防腦栓塞併髮癥是安全有效的。
목적:탐토항응치료비판막성방전(NVAF)적림상효과급약물선택。방법회고성분석본원근5년내과주원치료적NVAF환자96례,수궤분위화법령조32례,여화법령1.25~5 mg/d,유지국제표준화비치(INR)2.0~3.0;통심락효낭연합아사필림조32례,여통심락효낭0.78 g,3차/d,아사필림편100 mg/d;아사필림조32례,여아사필림편100 mg/d。관찰화비교삼조환자뇌전새급출혈등병발증발생솔,수방2년。결과뇌전새년발병솔화법령조(3.33%)여통심락효낭연합아사필림조(5.0%)비교차이무통계학의의(P>0.05);아사필림조(17.2%)여통심락효낭연합아사필림조비교차이유통계학의의(P<0.05);화법령조여아사필림조비교차이유통계학의의(P<0.01)。화법령조유1례뇌출혈;통심락효낭연합아사필림조유4례출현상복통、악심,1례출현아간종통;아사필림조유3례출현상복통、악심。결론통심락효낭연합아사필림예방NVAF환자뇌전새적효과화화법령비교차이무통계학의의,우우단용아사필림,무엄중불량반응발생,차불수요감측응혈매원시간(PT)화INR。불원의접수화법령치료적NVAF환자,급여통심락효낭연합아사필림예방뇌전새병발증시안전유효적。
Objective To explore the clinical effect and drug selection of nonvalvular atrial fibrillation (NVAF) by anticoagulation. Methods To analysis retrospectively the 96 NVAF patients with medical treatment in five years. The patients of warfarin group (n=32) took orally warfarin. The range of dosage was 1.25~5 mg/day and kept the INR between 2and 3. The patients of Tongxinluo capsule in combination with aspirin group (n=32) took orally Tongxinluo capsule (0.78 g,3 times a day) and aspirin (100 mg/d);Patients of aspirin group (n=32) took orally aspirin (100 mg/day). To observing and comparing the complication incidence of cerebral thromboembolism, hemorrhage etc, following up 2 years. Results The incidence of cerebral thromboembolism between warfarin group (3.33%/year) and Tongxinluo capsule combined with aspirin group (5.0%/year) had no remarkably significance (P>0.05).The result between aspirin group (17.2%/year) and Tongxinluo capsule combined with aspirin group had significance (P<0.05). The warfarin group between aspirin group had dramaticlly significance(P<0.01).The incidence of hemorrhage in warfarin group was 1.67%/year(n=1) and it was zero in the other two groups. Conclusion The effect of Tongxinluo capsule in combination with aspirin to prevent cerebral thromboembolism due to NVAF is same to that of warfarin and significantly better than that of aspirin.Tongxinluo capsule in combination with aspirin to prevent cerebral thromboembolism due to NVAF is safe and it does not need detecting INR. Tongxinluo capsule in combination with aspirin to prevent cerebral thromboembolism due to NVAF was effective and safety.